医健IPO解码 | 长期亏损难盈利，轩竹生物转战港股仍存挑战

七印授权

182OY4S16YQVUVFWCOXMWWRAO387ETAHSVFW3Q16TX33EUKM2V

2024-12-09 07:42:11

article

96BF840C03A716B2DDBC171EDAA43A5CE0EBE403D78AB92537C7E38F76A5B77B

zh-CN

6AA65AC6E96ABA00CD06D93C909C0BCCE448138B

17554563

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

10d5835f9f3efcd4b4ec3596cb438d9192f7946b496ba028034b3f7f8323d33b3742f8eb5a390992389b6ef1eeb5dd92edcbe19bef783e370e5399946b1dbd721c

{"parameters":{"adaptation":"n","price":"180000"},"type":"cm"}

yuanben_67569f53b9ffc8.76830549

原本认证

https://www.yuanben.io/article/e9b71c2a-33ec-4bd4-ab6b-c6eca3a0d5a8

{"author":"广东南方财经控股有限公司","authorization_pub_key":"03db333a8335fc94ab2e27ec5b937827ece2e576ae219f93ea1083a9a4f8882dc2"}